Prevalence of chronic kidney diseases in patients with chronic obstructive pulmonary disease: Assessment based on glomerular filtration rate estimated from creatinine and cystatin C levels

International Journal of COPD

Volumn 10, Issue , 2015, Pages 1283-1289

  Yoshizawa, Takayuki ^a,b   Okada, Kazuyoshi ^c   Furuichi, Sachiko ^a,b   Ishiguro, Toshihiko ^a   Yoshizawa, Akitaka ^a   Akahoshi, Toshiki ^b   Gon, Yasuhiro ^b   Akashiba, Tsuneto ^b   Hosokawa, Yoshifumi ^a,b   Hashimoto, Shu ^b  

^a Kanamecho Hospital   (Japan)

^b Respiratory Medicine   (Japan)

^c NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CKD; Comorbidity; COPD; eGFR

Indexed keywords

CREATININE; CYSTATIN C; BIOLOGICAL MARKER; CST3 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; ASTHMA; BODY MASS; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EVALUATION; COMORBIDITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DYSLIPIDEMIA; ENZYME BLOOD LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; BIOLOGICAL MODEL; BLOOD; CASE CONTROL STUDY; JAPAN; KIDNEY; MIDDLE AGED; ODDS RATIO; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS; CASE-CONTROL STUDIES; COMORBIDITY; CREATININE; CYSTATIN C; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; JAPAN; KIDNEY; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84937580139     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S80673     Document Type: Article

References (33)

1. Agustí AG, Noguera A, Sauleda J, Sala E, Pons J, Busquests X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J. 2003;21(2):347-360.
2. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33(5):1165-1185.
3. Soriano JB, Visick GT, Muellerova H, Payvandi N, Hansell AL. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest. 2005;128(4):2099-2107.
4. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008;32(4):962-969.
5. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: Role of comorbidities. Eur Respir J. 2006;28(6):1245-1257.
6. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2010. Global Initiative for Chronic Obstructive Lung Disease, Inc.; 2010. [cited April 1, 2011]. Available from: http://www.goldcopd.org/uploads/users/files/GOLDReport_April112011.pdf. Accessed April 1, 2011.
7. Cooper RG. Effect of tobacco smoking on renal function. Indian J Med Res. 2006;124(3):261-268.
8. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation. 2004;109(8):1004-1009.
9. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296-1305.
10. Manjunath G, Tighiouart H, Ibrahim H, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol. 2003;41(1):47-55.
11. van Gestel YR, Chonchol M, Hoeks SE, et al. Association between chronic obstructive pulmonary disease and chronic kidney disease in vascular surgery patients. Nephrol Dial Transplant. 2009;24(9):2763-2767.
12. Terzano C, Conti V, Di Stefano F, et al. Comorbidity, hospitalization, and mortality in COPD: results from a longitudinal study. Lung. 2010;188(4):321-329.
13. Casanova C, de Torres JP, Navarro J, et al. Microalbuminuria and hypoxemia in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;182(8):1004-1010.
14. Incalzi RA, Corsonello A, Pedone C, et al. Chronic renal failure: a neglected comorbidity of COPD. Chest. 2010;137(4):831-837.
15. Chandra D, Stamm JA, Palevsky PM, et al. The relationship between pulmonary emphysema and kidney function in smokers. Chest. 2012;142(3):655-662.
16. Corsonello A, Antonelli Incalzi R, Pistelli R, Pedone C, Bustacchini S, Lattanzio F. Comorbidities of chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2011;17 Suppl 1:S21-S28.
17. Hojs R, Bevc S, Antolinc B, Gorenjak M, Puklavec L. Serum cystatin C as an endogenous marker of renal function in the elderly. Int J Clin Pharmacol Res. 2004;24(2-3):49-54.
18. Coll E, Botey A, Alvarez L, et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis. 2000;36(1):29-34.
19. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis. 2002;40(2):221-226.
20. Yashiro M, Kamata T, Segawa H, Kadoya Y, Murakami T, Muso E. Comparisons of cystatin C with creatinine for evaluation of renal function in chronic kidney disease. Clin Exp Nephrol. 2009;13(6):598-604.
21. Hojs R, Bevc S, Ekart R, Gorenjak M, Puklavec L. Serum cystatin C as an endogenous marker of renal function in patients with mild to moderate impairment of kidney function. Nephrol Dial Transplant. 2006;21(7):1855-1862.
22. Hojs R, Bevc S, Ekart R, Gorenjak M, Puklavec L. Serum cystatin C-based formulas for prediction of glomerular filtration rate in patients with chronic kidney disease. Nephron Clin Pract. 2010;114(2):c118-c126.
23. Vupputuri S, Fox CS, Coresh J, Woodward M, Muntner P. Differential estimation of CKD using creatinine- versus cystatin C-based estimating equations by category of body mass index. Am J Kidney Dis. 2009;53(6):993-1001.
24. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982-992.
25. Horio M, Imai E, Yasuda Y, Watanabe T, Matsuo S; Collaborators Developing the Japanese Equation for Estimated GFR. GFR estimation using standardized serum cystatin C in Japan. Am J Kidney Dis. 2013;61(2):197-203.
26. Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011;80(1):17-28.
27. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007;116(1):85-97.
28. Koenig W, Twardella D, Brenner H, Rothenbacher D. Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. Clin Chem. 2005;51(2):321-327.
29. Shlipak MG, Katz R, Sarnak MJ, et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med. 2006;145(4):237-246.
30. Lee M, Saver JL, Huang WH, Chow J, Chang KH, Ovbiagele B. Impact of elevated cystatin C level on cardiovascular disease risk in predominantly high cardiovascular risk populations: a meta-analysis. Circ Cardiovasc Qual Outcomes. 2010;3(6):675-683.
31. Kiyosue A, Hirata Y, Ando J, et al. Plasma cystatin C concentration reflects the severity of coronary artery disease in patients without chronic kidney disease. Circ J. 2010;74(11):2441-2447.
32. Peralta CA, Katz R, Sarnak MJ, et al. Cystatin C identifies chronic kidney disease patients at higher risk for complications. J Am Soc Nephrol. 2011;22(1):147-155.
33. Damman K, van der Harst P, Smilde TD, et al. Use of cystatin C levels in estimating renal function and prognosis in patients with chronic systolic heart failure. Heart. 2012;98(4):319-324.